دورية أكاديمية
Precision medicine for severe asthma - Biological targeted therapy.
| العنوان: | Precision medicine for severe asthma - Biological targeted therapy. |
|---|---|
| المؤلفون: | Sun B; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Shen K; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Zhao R; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Li Y; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Xiang M; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Lin J; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: jiangtao_l@263.net. |
| المصدر: | International immunopharmacology [Int Immunopharmacol] 2024 Jun 15; Vol. 134, pp. 112189. Date of Electronic Publication: 2024 May 16. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam ; New York : Elsevier Science, c2001- |
| مواضيع طبية MeSH: | Asthma*/drug therapy , Asthma*/immunology , Precision Medicine*, Humans ; Anti-Asthmatic Agents/therapeutic use ; Biomarkers ; Animals ; Molecular Targeted Therapy ; Antibodies, Monoclonal/therapeutic use ; Cytokines/metabolism ; Biological Therapy/methods |
| مستخلص: | Severe asthma is a complex and heterogeneous chronic airway inflammatory disease. Current treatment strategies are increasingly focused on disease classification, facilitating the transition towards personalized medicine by integrating biomarkers and monoclonal antibodies for tailored therapeutic approaches. Several approved biological agents, including anti-immunoglobulin E (IgE), anti-interleukin (IL)-4, anti-IL-5, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have demonstrated significant efficacy in reducing asthma exacerbations, eosinophil counts, improving lung function, minimizing oral corticosteroid usage, and enhancing patients' quality of life. The utilization of these biological agents has brought about profound transformations in the management of severe asthma. This article provides a comprehensive review on biomarkers and biological agents for severe asthma while emphasizing the increasing importance of further research into its pathogenesis and novel treatment modalities. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Biological agents; Biomarkers; Precision medicine; Severe asthma |
| المشرفين على المادة: | 0 (Anti-Asthmatic Agents) 0 (Biomarkers) 0 (Antibodies, Monoclonal) 0 (Cytokines) |
| تواريخ الأحداث: | Date Created: 20240517 Date Completed: 20240602 Latest Revision: 20240602 |
| رمز التحديث: | 20240602 |
| DOI: | 10.1016/j.intimp.2024.112189 |
| PMID: | 38759375 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1878-1705 |
|---|---|
| DOI: | 10.1016/j.intimp.2024.112189 |